View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest Korányi S. u. 2/A 1083
Open access

Az elmúlt két évtizedben a biológiai (tumornekrózisfaktor-ellenes antitest) kezelések megjelenésével a Crohn-betegség és a colitis ulcerosa kezelési stratégiája jelentősen megváltozott, amelyben a biológiai kezelések egyre növekvő szerephez jutottak. Néhány betegben azonban nem észlelhető klinikai javulás, egyesekben pedig a fenntartó kezelés során csökken vagy elvész a kezelés hatékonysága. Hatásvesztés esetén a gyakorlati teendők megközelítése sokszor empirikus. Ebben az összefoglaló közleményben a szerzők a biológiai kezelés során tapasztalt hatásvesztés gyakoriságát és okait tekintik át, értékelve a klinikai tényezők, valamint a biológiai gyógyszerek szérumszintjének és az ellenük termelődött antitestek meghatározásának jelentőségét. A biológiai gyógyszerek szérumszintmérése és az ellenanyagok vizsgálata várhatóan fontos szerephez jut hatásvesztés esetén a szükséges teendők megítélésében az elkövetkező években. Alkalmazása hozzájárulhat a hatásvesztés okainak a feltérképezéséhez, megalapozottabbá teszi a dózismódosítást, segítséget nyújthat egy másik biológiai szerre vagy egy más, a betegség kialakulásában szerepet játszó faktor ellen ható biológiai szerre történő váltás indikációjában. Jelenleg nincsen a biológiai szerek ellen kialakult antitestek kimutatására optimális módszer, ezért a napi gyakorlatban hatásvesztés esetén a klinikai tünetek komplex, részletes értékelése, az aktív betegség és a szövődmények endoszkópos és/vagy képalkotó vizsgálata szükséges, és a biológiai szer váltása csak indokolt esetben javasolható. Orv. Hetil., 2012, 153, 163–173.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Cosnes, J., Cattan, S., Blain, A., et al.: Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel Dis., 2002, 8, 244–250.

    Blain A. , 'Long-term evolution of disease behavior of Crohn’s disease ' (2002 ) 8 Inflamm. Bowel Dis. : 244 -250.

    • Search Google Scholar
  • Bernell, O., Lapidus, A., Hellers, G.: Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann. Surg., 2000, 231, 38–45.

    Hellers G. , 'Risk factors for surgery and postoperative recurrence in Crohn’s disease ' (2000 ) 231 Ann. Surg. : 38 -45.

    • Search Google Scholar
  • Beaugerie, L., Seksik, P., Nion-Larmurier, I., et al.: Predictors of Crohn’s disease. Gastroenterology, 2006, 130, 650–656.

    Nion-Larmurier I. , 'Predictors of Crohn’s disease ' (2006 ) 130 Gastroenterology : 650 -656.

    • Search Google Scholar
  • Targan, S. R., Hanauer, S. B., van Deventer, S. J., et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med., 1997, 337, 1029–1035.

    Deventer S. J. , 'A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group ' (1997 ) 337 N. Engl. J. Med. : 1029 -1035.

    • Search Google Scholar
  • Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet, 2002, 359, 1541–1549.

    Lichtenstein G. R. , 'Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial ' (2002 ) 359 Lancet : 1541 -1549.

    • Search Google Scholar
  • Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology, 2004, 126, 402–413.

    Lichtenstein G. R. , 'Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease ' (2004 ) 126 Gastroenterology : 402 -413.

    • Search Google Scholar
  • Lichtenstein, G. R., Yan, S., Bala, M., et al.: Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am. J. Gastroenterol., 2004, 99, 91–96.

    Bala M. , 'Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries ' (2004 ) 99 Am. J. Gastroenterol. : 91 -96.

    • Search Google Scholar
  • Feagan, B. G., Yan, S., Bala, M., et al.: The effects of infliximab maintenance therapy on health-related quality of life. Am. J. Gastroenterol., 2003, 98, 2232–2238.

    Bala M. , 'The effects of infliximab maintenance therapy on health-related quality of life ' (2003 ) 98 Am. J. Gastroenterol. : 2232 -2238.

    • Search Google Scholar
  • Baert, F., Moortgat, L., Van Assche, G., et al.: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology, 2010, 138, 463–468.

    Assche G. , 'Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease ' (2010 ) 138 Gastroenterology : 463 -468.

    • Search Google Scholar
  • Schnitzler, F., Fidder, H., Ferrante, M., et al.: Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm. Bowel Dis., 2009, 15, 1295–1301.

    Ferrante M. , 'Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease ' (2009 ) 15 Inflamm. Bowel Dis. : 1295 -1301.

    • Search Google Scholar
  • Present, D. H., Rutgeerts, P., Targan, S., et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med., 1999, 340, 1398–1405.

    Targan S. , 'Infliximab for the treatment of fistulas in patients with Crohn’s disease ' (1999 ) 340 N. Engl. J. Med. : 1398 -1405.

    • Search Google Scholar
  • Schnitzler, F., Fidder, H., Ferrante, M., et al.: Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut, 2009, 58, 492–500.

    Ferrante M. , 'Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort ' (2009 ) 58 Gut : 492 -500.

    • Search Google Scholar
  • Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology, 2006, 130, 323–333.

    Rutgeerts P. , 'Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial ' (2006 ) 130 Gastroenterology : 323 -333.

    • Search Google Scholar
  • Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., et al.: Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut, 2007, 56, 1232–1239.

    Rutgeerts P. , 'Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial ' (2007 ) 56 Gut : 1232 -1239.

    • Search Google Scholar
  • Colombel, J. F., Sandborn, W. J., Rutgeerts, P., et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology, 2007, 132, 52–65.

    Rutgeerts P. , 'Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial ' (2007 ) 132 Gastroenterology : 52 -65.

    • Search Google Scholar
  • Kamm, M. A., Hanauer, S. B., Panaccione, R., et al.: Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease. Aliment. Pharmacol. Ther., 2011, 34, 306–317.

    Panaccione R. , 'Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease ' (2011 ) 34 Aliment. Pharmacol. Ther. : 306 -317.

    • Search Google Scholar
  • Sandborn, W. J., Rutgeerts, P., Enns, R., et al.: Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med., 2007, 146, 829–838.

    Enns R. , 'Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial ' (2007 ) 146 Ann. Intern. Med. : 829 -838.

    • Search Google Scholar
  • Panaccione, R., Enns, R., Wolf, D. C., et al.: Adalimumab maintains long-term remission in Crohn’s disease after infliximab failure: 1-Year Follow-up of GAIN Trial. ECCO Conference. J. Crohn Colitis, 2008, 2, S–303.

    Wolf D. C. , 'Adalimumab maintains long-term remission in Crohn’s disease after infliximab failure: 1-Year Follow-up of GAIN Trial. ECCO Conference ' (2008 ) 2 J. Crohn Colitis : S -303.

    • Search Google Scholar
  • Rutgeerts, P., D’Haens, R. G., Van Assche, G., et al.: Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn’s disease: first results of the extend trial. Gastroenterology, 2009, 136 (Suppl. 1), 751e.

    Assche G. , 'Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn’s disease: first results of the extend trial ' (2009 ) 136 Gastroenterology : 751e -.

    • Search Google Scholar
  • Hommes, D. W. B. F., Van Assche, G.: Management of recent onset Crohn’s disease: a controlled randomized trial comparing step-up and top-down therapy. Gastroenterology, 2005, 128 (Suppl. 1), A577.

    Assche G. , 'Management of recent onset Crohn’s disease: a controlled randomized trial comparing step-up and top-down therapy ' (2005 ) 128 Gastroenterology : A577 -.

    • Search Google Scholar
  • D’Haens, G., Baert, F., Van Assche, G., et al.: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet, 2008, 371, 660–667.

    Assche G. , 'Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial ' (2008 ) 371 Lancet : 660 -667.

    • Search Google Scholar
  • Colombel, J. F., Sandborn, W. J., Reinisch, W., et al.: Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med., 2010, 362, 1383–1395.

    Reinisch W. , 'Infliximab, azathioprine, or combination therapy for Crohn’s disease ' (2010 ) 362 N. Engl. J. Med. : 1383 -1395.

    • Search Google Scholar
  • Leijonmarck, C. E., Persson, P. G., Hellers, G.: Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut, 1990, 31, 329–333.

    Hellers G. , 'Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study ' (1990 ) 31 Gut : 329 -333.

    • Search Google Scholar
  • Ingle, S. B. DS., Harmsen, W. S.: Risk factors for ulcerative colitis (UC) surgery in a population-based cohort (abstract). Am. J. Gastroenterol., 2007, 102, S480–S481.

    Harmsen W. S. , 'Risk factors for ulcerative colitis (UC) surgery in a population-based cohort (abstract) ' (2007 ) 102 Am. J. Gastroenterol. : S480 -S481.

    • Search Google Scholar
  • Loftus, E. V. Jr., Friedman, H. S., Delgado, D. J., et al.: Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm. Bowel Dis., 2009, 15, 566–575.

    Delgado D. J. , 'Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States ' (2009 ) 15 Inflamm. Bowel Dis. : 566 -575.

    • Search Google Scholar
  • Hoie, O., Wolters, F. L., Riis, L., et al.: Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology, 2007, 132, 507–515.

    Riis L. , 'Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years ' (2007 ) 132 Gastroenterology : 507 -515.

    • Search Google Scholar
  • Lakatos, L., Kiss, L. S., David, G., et al.: Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006. Inflam. Bowel Dis., 2011, 17. In press

  • Jarnerot, G., Hertervig, E., Friis-Liby, I., et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology, 2005, 128, 1805–1811.

    Friis-Liby I. , 'Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study ' (2005 ) 128 Gastroenterology : 1805 -1811.

    • Search Google Scholar
  • Gustavsson, A. J. G., Hrtervig, E.: A 2-year follow up of the Swedish-Danish infliximab/placebo trial in steroid resistant acute ulcerative colitis. Gastroenterology, 2007, 132 (Suppl 1), A–146.

    Hrtervig E. , 'A 2-year follow up of the Swedish-Danish infliximab/placebo trial in steroid resistant acute ulcerative colitis ' (2007 ) 132 Gastroenterology : A -146.

    • Search Google Scholar
  • Rutgeerts, P., Sandborn, W. J., Feagan, B. G., et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Eng. J. Med., 2005, 353, 2462–2476.

    Feagan B. G. , 'Infliximab for induction and maintenance therapy for ulcerative colitis ' (2005 ) 353 N. Eng. J. Med. : 2462 -2476.

    • Search Google Scholar
  • Reinisch, W., Sandborn, W. J., Hommes, D. W., et al.: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut, 2011, 60, 780–787.

    Hommes D. W. , 'Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial ' (2011 ) 60 Gut : 780 -787.

    • Search Google Scholar
  • Allez, M., Karmiris, K., Louis, E., et al.: Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J. Crohn. Colitis, 2010, 4, 355–366.

    Louis E. , 'Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects ' (2010 ) 4 J. Crohn. Colitis : 355 -366.

    • Search Google Scholar
  • Gisbert, J. P., Panes, J.: Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am. J. Gastroenterol., 2009, 104, 760–767.

    Panes J. , 'Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review ' (2009 ) 104 Am. J. Gastroenterol. : 760 -767.

    • Search Google Scholar
  • De Ridder, L., Rings, E. H., Damen, G. M., et al.: Infliximab dependency in pediatric Crohn’s disease: long-term follow-up of an unselected cohort. Inflam. Bowel Dis., 2008, 14, 353–358.

    Damen G. M. , 'Infliximab dependency in pediatric Crohn’s disease: long-term follow-up of an unselected cohort ' (2008 ) 14 Inflam. Bowel Dis. : 353 -358.

    • Search Google Scholar
  • Sands, B. E., Anderson, F. H., Bernstein, C. N., et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med., 2004, 350, 876–885.

    Bernstein C. N. , 'Infliximab maintenance therapy for fistulizing Crohn’s disease ' (2004 ) 350 N. Engl. J. Med. : 876 -885.

    • Search Google Scholar
  • Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., et al.: Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med., 2007, 357, 239–250.

    Lawrance I. C. , 'Maintenance therapy with certolizumab pegol for Crohn’s disease ' (2007 ) 357 N. Engl. J. Med. : 239 -250.

    • Search Google Scholar
  • Baert, F., Noman, M., Vermeire, S., et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med., 2003, 348, 601–608.

    Vermeire S. , 'Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease ' (2003 ) 348 N. Engl. J. Med. : 601 -608.

    • Search Google Scholar
  • Billioud, V., Sandborn, W. J., Peyrin-Biroulet, L.: Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am. J Gastroenterol., 2011, 106, 674–684.

    Peyrin-Biroulet L. , 'Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review ' (2011 ) 106 Am. J Gastroenterol. : 674 -684.

    • Search Google Scholar
  • Hanauer, S. B., Wagner, C. L., Bala, M., et al.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin. Gastroenterol. Hepatol., 2004, 2, 542–553.

    Bala M. , 'Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease ' (2004 ) 2 Clin. Gastroenterol. Hepatol. : 542 -553.

    • Search Google Scholar
  • Karmiris, K., Paintaud, G., Noman, M., et al.: Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology, 2009, 137, 1628–1640.

    Noman M. , 'Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease ' (2009 ) 137 Gastroenterology : 1628 -1640.

    • Search Google Scholar
  • Kiss, L. S., Szamosi, T., Molnar, T., et al.: Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment. Pharmacol. Ther., 2011, 34, 911–922.

    Molnar T. , 'Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease ' (2011 ) 34 Aliment. Pharmacol. Ther. : 911 -922.

    • Search Google Scholar
  • Klotz, U., Teml, A., Schwab, M.: Clinical pharmacokinetics and use of infliximab. Clin. Pharmacokinet., 2007, 46, 645–660.

    Schwab M. , 'Clinical pharmacokinetics and use of infliximab ' (2007 ) 46 Clin. Pharmacokinet. : 645 -660.

    • Search Google Scholar
  • Ben-Horin, S., Yavzori, M., Katz, L., et al.: The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut, 2011, 60, 41–48.

    Katz L. , 'The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful ' (2011 ) 60 Gut : 41 -48.

    • Search Google Scholar
  • Kopylov, U., Mazor, Y., Yavzori, M., et al.: Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm. Bowel Dis., 2011. in press

  • Imaeda, H., Andoh, A., Fujiyama, Y.: Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J. Gastroenterol., 2011 Sep 28. [Epub ahead of print.]

  • Maini, R. N., Breedveld, F. C., Kalden, J. R., et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum., 1998, 41, 1552–1563.

    Kalden J. R. , 'Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis ' (1998 ) 41 Arthritis Rheum. : 1552 -1563.

    • Search Google Scholar
  • Svenson, M., Geborek, P., Saxne, T., et al.: Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford), 2007, 46, 1828–1834.

    Saxne T. , 'Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies ' (2007 ) 46 Rheumatology (Oxford) : 1828 -1834.

    • Search Google Scholar
  • Wolbink, G. J., Voskuyl, A. E., Lems, W. F., et al.: Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2005, 64, 704–707.

    Lems W. F. , 'Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis ' (2005 ) 64 Ann. Rheum. Dis. : 704 -707.

    • Search Google Scholar
  • Bartelds, G. M., Krieckaert, C. L., Nurmohamed, M. T., et al.: Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA, 2011, 305, 1460–1468.

    Nurmohamed M. T. , 'Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up ' (2011 ) 305 JAMA : 1460 -1468.

    • Search Google Scholar
  • Maser, E. A., Villela, R., Silverberg, M. S., et al.: Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin. Gastroenterol. Hepatol., 2006, 4, 1248–1254.

    Silverberg M. S. , 'Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease ' (2006 ) 4 Clin. Gastroenterol. Hepatol. : 1248 -1254.

    • Search Google Scholar
  • Seow, C. H., Newman, A., Irwin, S. P., et al.: Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut, 2010, 59, 49–54.

    Irwin S. P. , 'Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis ' (2010 ) 59 Gut : 49 -54.

    • Search Google Scholar
  • West, R. L., Zelinkova, Z., Wolbink, G. J., et al.: Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment. Pharmacol. Ther., 2008, 28, 1122–1126.

    Wolbink G. J. , 'Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease ' (2008 ) 28 Aliment. Pharmacol. Ther. : 1122 -1126.

    • Search Google Scholar
  • Vermeire, S., Noman, M., Van Assche, G., et al.: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut, 2007, 56, 1226–1231.

    Assche G. , 'Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease ' (2007 ) 56 Gut : 1226 -1231.

    • Search Google Scholar
  • Ainsworth, M. A., Bendtzen, K., Brynskov, J.: Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. Am. J. Gastroenterol., 2008, 103, 944–948.

    Brynskov J. , 'Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease ' (2008 ) 103 Am. J. Gastroenterol. : 944 -948.

    • Search Google Scholar
  • Ben-Horin, S., Chowers, Y.: Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment. Pharmacol. Ther., 2011, 33, 987–995.

    Chowers Y. , 'Review article: loss of response to anti-TNF treatments in Crohn’s disease ' (2011 ) 33 Aliment. Pharmacol. Ther. : 987 -995.

    • Search Google Scholar
  • Schwab, M., Klotz, U.: Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin. Pharmacokinet., 2001, 40, 723–751.

    Klotz U. , 'Pharmacokinetic considerations in the treatment of inflammatory bowel disease ' (2001 ) 40 Clin. Pharmacokinet. : 723 -751.

    • Search Google Scholar
  • Roblin, X., Serre-Debeauvais, F., Phelip, J. M., et al.: Drug interaction between infliximab and azathioprine in patients with Crohn’s disease. Aliment. Pharmacol. Ther., 2003, 18, 917–925.

    Phelip J. M. , 'Drug interaction between infliximab and azathioprine in patients with Crohn’s disease ' (2003 ) 18 Aliment. Pharmacol. Ther. : 917 -925.

    • Search Google Scholar
  • Billioud, V., Laharie, D., Filippi, J., et al.: Adherence to adalimumab therapy in Crohn’s disease: a French multicenter experience. Inflam. Bowel Dis., 2011, 17, 152–159.

    Filippi J. , 'Adherence to adalimumab therapy in Crohn’s disease: a French multicenter experience ' (2011 ) 17 Inflam. Bowel Dis. : 152 -159.

    • Search Google Scholar
  • Kopylov, U., Mantzaris, G. J., Katsanos, K. H., et al.: The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab. Aliment. Pharmacol. Ther., 2011, 33, 349–357.

    Katsanos K. H. , 'The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab ' (2011 ) 33 Aliment. Pharmacol. Ther. : 349 -357.

    • Search Google Scholar
  • Afif, W., Loftus, E. V. Jr., Faubion, W. A., et al.: Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol., 2010, 105, 1133–1139.

    Faubion W. A. , 'Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease ' (2010 ) 105 Am. J. Gastroenterol. : 1133 -1139.

    • Search Google Scholar
  • Farrell, R. J., Alsahli, M., Jeen, Y. T., et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology, 2003, 124, 917–924.

    Jeen Y. T. , 'Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial ' (2003 ) 124 Gastroenterology : 917 -924.

    • Search Google Scholar
  • Van Assche, G., Magdelaine-Beuzelin, C., D’Haens, G., et al.: Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology, 2008, 134, 1861–1868.

    D’Haens G. , 'Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial ' (2008 ) 134 Gastroenterology : 1861 -1868.

    • Search Google Scholar
  • Van Assche, G., Vermeire, S., Ballet, V., et al.: Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut, 2011 Sep 23. [Epub ahead of print]

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

Mendeley citation style is available HERE.

 

MANUSCRIPT SUBMISSION

  • Impact Factor (2018): 0.564
  • Medicine (miscellaneous) SJR Quartile Score (2018): Q3
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu